US Stock Market Movement: $80 billion financing plan shocks the market, Google A drops over 4% to hit a new one-month low

On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)

Latest Updates October 8 - Chipotle Mexican Grill shares (CMG.N) surged by as much as 8.55% to $33.40, while Starbucks (SBUX.O) shares once dropped 6.66% to $87.35. The Financial Times, citing insiders, reported that Starbucks (SBUX) had considered acquiring Chipotle (link). The coffee giant's stock has fallen to its lowest point since March. According to the report, the progress of the acquisition plan remains unclear; both Starbucks and Chipotle did not immediately respond to Reuters' requests for comment. If the deal goes through, CEO Brian Niccol would return to lead the Mexican grill chain he ran before joining the coffee giant two years ago. "For SBUX, we think investors would view this as a distraction for management's time and energy—after all, there is still much work to be done to revive the Starbucks brand, particularly concerning the fundamentals of same-store sales in North America, as the company gradually exhausts easily achievable growth points through 2027 and beyond," said RBC Capital Markets analyst Logan Reich. According to data from the London Stock Exchange Group (LSEG), CMG has a market capitalization of about $39 billions, while SBUX is valued at $107 billions. As of the close of the last trading day, SBUX has risen about 11% year-to-date, while CMG has fallen by 17%. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may be inaccurate or lack contextual nuances, Reuters does not guarantee the accuracy of translated texts, which are provided solely for reader convenience. Reuters accepts no liability for any loss or damage arising from the use of automated translations.)